0001104659-23-082726.txt : 20230720
0001104659-23-082726.hdr.sgml : 20230720
20230720161700
ACCESSION NUMBER: 0001104659-23-082726
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230718
FILED AS OF DATE: 20230720
DATE AS OF CHANGE: 20230720
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kemble George
CENTRAL INDEX KEY: 0001858176
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41742
FILM NUMBER: 231099911
MAIL ADDRESS:
STREET 1: SAGIMET BIOSCIENCES INC.
STREET 2: 155 BOVET RD., STE. 303
CITY: SAN MATEO
STATE: CA
ZIP: 94402
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sagimet Biosciences Inc.
CENTRAL INDEX KEY: 0001400118
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205991472
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 155 BOVET RD., SUITE 303
CITY: SAN MATEO
STATE: CA
ZIP: 94402
BUSINESS PHONE: (650) 561-8600
MAIL ADDRESS:
STREET 1: 155 BOVET RD., SUITE 303
CITY: SAN MATEO
STATE: CA
ZIP: 94402
FORMER COMPANY:
FORMER CONFORMED NAME: 3-V Biosciences, Inc.
DATE OF NAME CHANGE: 20070521
4
1
tm2321276-16_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-07-18
0
0001400118
Sagimet Biosciences Inc.
SGMT
0001858176
Kemble George
SAGIMET BIOSCIENCES INC.
155 BOVET RD., SUITE 303
SAN MATEO
CA
94402
1
0
0
0
0
Stock Option (Right to Buy)
0.79
2023-07-18
4
D
0
5630
0
D
2023-09-26
Common Stock
5630
0
D
Stock Option (Right to Buy)
0.79
2023-07-18
4
A
0
5630
0
A
2023-09-26
Series A Common Stock
5630
5630
D
Stock Option (Right to Buy)
11.13
2023-07-18
4
D
0
3179
0
D
2024-03-12
Common Stock
3179
0
D
Stock Option (Right to Buy)
11.13
2023-07-18
4
A
0
3179
0
A
2024-03-12
Series A Common Stock
3179
3179
D
Stock Option (Right to Buy)
23.05
2023-07-18
4
D
0
7147
0
D
2024-12-16
Common Stock
7147
0
D
Stock Option (Right to Buy)
23.05
2023-07-18
4
A
0
7147
0
A
2024-12-16
Series A Common Stock
7147
7147
D
Stock Option (Right to Buy)
19.87
2023-07-18
4
D
0
26352
0
D
2025-10-12
Common Stock
26352
0
D
Stock Option (Right to Buy)
19.87
2023-07-18
4
A
0
26352
0
A
2025-10-12
Series A Common Stock
26352
26352
D
Stock Option (Right to Buy)
6.36
2023-07-18
4
D
0
367824
0
D
2029-04-27
Common Stock
367824
0
D
Stock Option (Right to Buy)
6.36
2023-07-18
4
A
0
367824
0
A
2029-04-27
Series A Common Stock
367824
367824
D
Stock Option (Right to Buy)
6.36
2023-07-18
4
D
0
46432
0
D
2029-04-27
Common Stock
46432
0
D
Stock Option (Right to Buy)
6.36
2023-07-18
4
A
0
46432
0
A
2029-04-27
Series A Common Stock
46432
46432
D
Stock Option (Right to Buy)
6.36
2023-07-18
4
D
0
526332
0
D
2031-01-26
Common Stock
526332
0
D
Stock Option (Right to Buy)
6.36
2023-07-18
4
A
0
526332
0
A
2031-01-26
Series A Common Stock
526332
526332
D
Stock Option (Right to Buy)
7.15
2023-07-18
4
D
0
21173
0
D
2032-10-16
Common Stock
21173
0
D
Stock Option (Right to Buy)
7.15
2023-07-18
4
A
0
21173
0
A
2032-10-16
Series A Common Stock
21173
21173
D
Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
This option is fully vested and exercisable as of the date hereof.
The shares underlying this option vest and become exercisable in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date.
25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
/s/ Dennis Hom, Attorney-in-Fact
2023-07-20